Pulmatrix (PULM) Stock Price

Pulmatrix Price

NASDAQ·CLOSED
1.40
​
Market closed

Revenue has compounded at 23.0% per year over the past 12 years to 7.81 M USD. Pulmatrix's net margin stands at -122.5%, up from -152.8% several years earlier.

Pulmatrix stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulmatrix business model & stock analysis

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The company is headquartered in Lexington, Massachusetts and currently employs 22 full-time employees. The company went IPO on 2014-03-21. The firm is focused on developing inhaled therapies to address serious respiratory disease. The firm designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways. iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with a broad range of drug substances including small molecules and biologics. The Company’s therapeutic candidates are Pulmazole, PUR1800, PUR5700, PUR3000 and PUR4000.

Frequently asked questions about Pulmatrix

7 analysts currently rate the Pulmatrix stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pulmatrix to generate revenue of 16.45 M USD and earnings per share of -2.24 USD.

Converted at the current exchange rate, the Pulmatrix share trades at 1.25 EUR (1.40 USD).

The Pulmatrix share (PULM) is listed on 1 stock exchanges, including: NASDAQ (PULM).

The expected revenue of Pulmatrix is 16.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pulmatrix is -8.18 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pulmatrix is currently -0.63. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pulmatrix stock.

The price-to-sales ratio (P/S) of Pulmatrix is currently 0.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pulmatrix stock.

The Eulerpool Quality Score for Pulmatrix is 2/10.

The ISIN of Pulmatrix is US74584P3010. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Pulmatrix is A2PD3T. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Pulmatrix is PULM. The ticker symbol is used to trade Pulmatrix shares on the stock exchange.

Fair ValueTerminal
1.22 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 21, 2014
ISIN
US74584P3010
Cusip
74584P202
Sedol
BJHTCB7
Market capitalization
5.11 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.63
P/Ee 2027
2.41
P/Ee 2028
0.46
P/Ee 2029
0.35
P/S
P/Se
0.31
EV/EBIT
—
P/B Ratio
1.34
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-135.49 %
Last updated Oct 20, 2026, 9:06 AM

All fundamentals and in-depth analysis of Pulmatrix

Our stock analysis for Pulmatrix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pulmatrix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.